With a decision dated 25.07.2024 and numbered 24-31/729-M, the Competition Board took under final examination the application concerning the acquisition of sole control over Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret AŞ, which is active in the production and sales of goods used in nuclear medicine, by Curium International Trading B.V.

The assessment made suggests that the relevant transaction may create dominant position or strengthen an existing dominant position as set out under Article 7 of the Act no 4054, resulting in a significant decrease in effective competition in the whole country or a significant portion thereof.

As known, article 7 of the Act no 4054 on the protection of Competition tasks the Competition Board with the duty to supervise merger and/or acquisition transactions that could will result in a significant decrease in effective competition within markets. Within the framework of article 10 of the Act, the Board may take those transactions that require a more in-depth examination in terms of their effect on the competitive structure under final examination. In accordance with article 10 of the Act, a merger/acquisition transaction notified to the Board is suspended until the final decision is taken and may not be implemented.